Company / R&D Expense
Cardiff Oncology, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$35.3M
FY2025
5-year range
$17.4M / $35.3M
FY2021-FY2025
Trend
+7.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 7 consecutive years, from $8M in FY2018 to $35M in FY2025.
Based on SEC 10-K filings.
$35M in FY2025 with a 5-year CAGR of +25.8%.
Improved from $27M to $35M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +9.2%
- 5-Year CAGR
- +25.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Cardiff Oncology, Inc.'s r&d expense has grown for 7 consecutive years.
- 5-year CAGR of +25.8%, indicating consistent growth.
- In FY2025, r&d expense increased 7.5% year-over-year.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $35.3M | +7.5% |
| FY2024 | $32.9M | +21.2% |
| FY2023 | $27.1M | +0.0% |
| FY2022 | $27.1M | +55.7% |
| FY2021 | $17.4M | +54.9% |
| FY2020 | $11.2M | +0.7% |
| FY2019 | $11.2M | +41.6% |
| FY2018 | $7.9M | -47.5% |
| FY2017 | $15.0M | +125.2% |
| FY2016 | $6.7M | -37.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026